Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second‐line treatment for non–small‐cell lung cancer wild‐type or unknown status for EGFR
Información
- DOI:
- https://doi.org/10.1002/14651858.CD012901Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 11 enero 2018see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Protocol
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Cáncer de pulmón
- Copyright:
-
- Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Perrine Créquit, Amelie Yavchitz, Jacques Cadranel, Ludovic Trinquart and Philippe Ravaud have conceived and designed the review and the search strategy. They will interpret the data.
Perrine Créquit and Amelie Yavchitz will undertake searches including for unpublished studies. They will screen retrieved papers against eligibility criteria, appraise the quality of papers, and extract data from papers. Perrine Créquit will enter data.
Perrine Créquit, Ludovic Trinquart, and Jacques Cadranel will analyse the data. Perrine Créquit, Jacques Cadranel, Ludovic Trinquart, and Philippe Ravaud will write the review.
Sources of support
Internal sources
-
No sources of support, Other.
External sources
-
No sources of support, Other.
Declarations of interest
| Perrine Créquit | Amelie Yavchitz | Jacques Cadranel | Ludovic Trinquart | Philippe Ravaud | |
| Expertise | None | None | Astra Zeneca, Boehringer Ingelheim, Roche, Lilly, Pfizer, BMS, Novartis | None | None |
| Congress | None | None | Roche, Boehringer Ingelheim | None | None |
| Intervention | None | None | None | None | None |
| Research funding | None | None | Boehringer Ingelheim, Novartis, Pfizer | None | None |
Acknowledgements
We acknowledge the Cochrane Lung Group for its valuable assistance, in particular Prof. Virginie Westeel (Joint Co‐coordinating Editor of the Cochrane Lung Cancer Group) and Corynne Marchal (Managing Editor of the Cochrane Lung Cancer Group) for their support and advice, as well as Francois Calais and Giorgio Maria Agazzi, Information Specialists of the Lung Cancer Group for their work on the design of our search strategies. We acknowledge the assistance of Dr. Fergus Macbeth (Joint Co‐coordinating Editor of the Cochrane Lung Cancer Group) and we also thank Lars Lidgard (consumer of the Lung Cancer Group) for his feedback.
Version history
| Published | Title | Stage | Authors | Version |
| 2018 Jan 11 | Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second‐line treatment for non–small‐cell lung cancer wild‐type or unknown status for EGFR | Protocol | Perrine Créquit, Amelie Yavchitz, Ludovic Trinquart, Philippe Ravaud, Jacques Cadranel | |
